colchicine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	726	64-86-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: colchicine colchisol colcin	A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Potential to limit COVID-19-related myocardial damage has been hypothesized based on the drug’s mechanisms of action and promising results of ongoing research on colchicine in various cardiac conditions. However, the drug's safety and efficacy for treatment of COVID-19 is not yet established. Molecular weight: 399.44 Formula: C22H25NO6 CLOGP: 1.20 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 83.09 ALOGS: -4.16 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

colchicine
colchisol
colcin

A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Potential to limit COVID-19-related myocardial damage has been hypothesized based on the drug’s mechanisms of action and promising results of ongoing research on colchicine in various cardiac conditions. However, the drug's safety and efficacy for treatment of COVID-19 is not yet established.

Molecular weight: 399.44
Formula: C22H25NO6
CLOGP: 1.20
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 83.09
ALOGS: -4.16
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	O
1	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.29 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ
S (Water solubility)	45 mg/mL	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	6.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.61 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	58 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 27, 1961	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gout	292.88	12.82	130	21444	11226	46653262
Panniculitis	124.00	12.82	58	21516	5646	46658842
Enthesopathy	121.87	12.82	54	21520	4636	46659852
Tenosynovitis	106.03	12.82	57	21517	7458	46657030
Blood parathyroid hormone decreased	96.63	12.82	45	21529	4336	46660152
Red blood cell sedimentation rate	89.80	12.82	33	21541	1740	46662748
Granuloma skin	87.10	12.82	39	21535	3431	46661057
Acute kidney injury	80.00	12.82	265	21309	235590	46428898
Drug interaction	78.75	12.82	239	21335	202855	46461633
Tongue disorder	78.13	12.82	46	21528	7164	46657324
Skin necrosis	78.09	12.82	49	21525	8555	46655933
Drug reaction with eosinophilia and systemic symptoms	76.97	12.82	81	21493	29467	46635021
Urticarial vasculitis	75.95	12.82	21	21553	433	46664055
Rheumatoid nodule	73.51	12.82	48	21526	8972	46655516
Diarrhoea	70.46	12.82	470	21104	559132	46105356
Toxicity to various agents	67.42	12.82	233	21341	211533	46452955
Tendonitis	66.17	12.82	54	21520	14223	46650265
Hypersensitivity vasculitis	62.31	12.82	33	21541	4188	46660300
Ulcer	56.95	12.82	54	21520	17338	46647150
Rhabdomyolysis	52.93	12.82	80	21494	41829	46622659
Hypercalcaemia	51.81	12.82	56	21518	20990	46643498
Loss of employment	51.38	12.82	20	21554	1236	46663252
Drug resistance	45.91	12.82	48	21526	17320	46647168
Familial mediterranean fever	45.46	12.82	9	21565	37	46664451
Drug eruption	44.38	12.82	52	21522	21277	46643211
Gouty tophus	43.06	12.82	11	21563	165	46664323
Skin ulcer	42.47	12.82	63	21511	32395	46632093
Psoriatic arthropathy	41.13	12.82	66	21508	36313	46628175
C-reactive protein abnormal	39.58	12.82	49	21525	21221	46643267
Basal cell carcinoma	39.42	12.82	48	21526	20439	46644049
Pericarditis	38.06	12.82	51	21523	23876	46640612
Aspartate aminotransferase increased	35.60	12.82	98	21476	78602	46585886
Chronic kidney disease	34.27	12.82	65	21509	40806	46623682
Pericardial effusion	34.02	12.82	50	21524	25493	46638995
Multiple organ dysfunction syndrome	33.60	12.82	74	21500	51636	46612852
Enterococcal sepsis	33.43	12.82	15	21559	1325	46663163
Alanine aminotransferase increased	33.16	12.82	103	21471	88348	46576140
Pancytopenia	32.77	12.82	100	21474	84958	46579530
Hepatocellular injury	32.61	12.82	53	21521	29469	46635019
Myopathy	31.82	12.82	29	21545	8852	46655636
Neuromyopathy	31.22	12.82	11	21563	513	46663975
Metabolic acidosis	30.47	12.82	60	21514	38720	46625768
Alanine aminotransferase abnormal	29.70	12.82	17	21557	2510	46661978
Rash pruritic	29.55	12.82	64	21510	44151	46620337
Drug intolerance	29.27	12.82	140	21434	146909	46517579
Acute febrile neutrophilic dermatosis	28.74	12.82	17	21557	2668	46661820
International normalised ratio increased	28.12	12.82	65	21509	46818	46617670
Behcet's syndrome	27.79	12.82	7	21567	99	46664389
C-reactive protein increased	27.53	12.82	74	21500	58516	46605972
Fear of injection	26.51	12.82	19	21555	4128	46660360
Gouty arthritis	24.07	12.82	9	21565	498	46663990
Parotid gland enlargement	23.42	12.82	10	21564	784	46663704
Hypertriglyceridaemia	23.17	12.82	20	21554	5684	46658804
Blood creatine phosphokinase increased	23.12	12.82	44	21530	27680	46636808
Appetite disorder	22.53	12.82	19	21555	5235	46659253
Red blood cell sedimentation rate increased	22.49	12.82	39	21535	22850	46641638
Leukopenia	22.37	12.82	76	21498	68267	46596221
Disseminated intravascular coagulation	20.82	12.82	34	21540	18971	46645517
Seizure	20.61	12.82	16	21558	123038	46541450
Iodine allergy	19.77	12.82	8	21566	548	46663940
Inflammation	19.39	12.82	58	21516	48723	46615765
Loss of personal independence in daily activities	19.07	12.82	64	21510	57119	46607369
Hyperferritinaemia	19.04	12.82	5	21569	84	46664404
Amegakaryocytic thrombocytopenia	18.95	12.82	4	21570	24	46664464
Natural killer cell count	18.95	12.82	4	21570	24	46664464
Maternal exposure during pregnancy	18.94	12.82	12	21562	102537	46561951
Bone marrow failure	18.75	12.82	42	21532	29627	46634861
Macrophages increased	18.54	12.82	4	21570	27	46664461
Chondrocalcinosis pyrophosphate	18.35	12.82	9	21565	972	46663516
Rash maculo-papular	18.22	12.82	40	21534	27834	46636654
Allergy to metals	17.95	12.82	7	21567	435	46664053
Acarodermatitis	17.77	12.82	8	21566	712	46663776
Axial spondyloarthritis	17.61	12.82	5	21569	114	46664374
Myopathy toxic	17.15	12.82	6	21568	274	46664214
Cutaneous tuberculosis	16.53	12.82	5	21569	143	46664345
Malignant neoplasm progression	16.06	12.82	5	21569	64921	46599567
Meningocele	15.89	12.82	3	21571	9	46664479
Polyarteritis nodosa	15.84	12.82	6	21568	344	46664144
Autoinflammatory disease	15.66	12.82	4	21570	60	46664428
Therapy non-responder	15.48	12.82	48	21526	41104	46623384
Drug abuse	15.47	12.82	5	21569	63403	46601085
Joint injury	15.42	12.82	30	21544	19179	46645309
Drug hypersensitivity	15.26	12.82	176	21398	243649	46420839
Myalgia	15.09	12.82	103	21471	122985	46541503
Synovitis	15.04	12.82	62	21512	61013	46603475
Cardiac tamponade	14.90	12.82	14	21560	4440	46660048
White blood cell count decreased	14.84	12.82	18	21556	112213	46552275
Toxic epidermal necrolysis	14.60	12.82	32	21542	22246	46642242
Memory impairment	14.34	12.82	9	21565	77328	46587160
Vasculitis	14.31	12.82	24	21550	13687	46650801
Product use issue	13.95	12.82	83	21491	94561	46569927
White blood cells urine positive	13.93	12.82	13	21561	4087	46660401
Febrile neutropenia	13.80	12.82	14	21560	94613	46569875
Mesenteric vein thrombosis	13.73	12.82	7	21567	821	46663667
Angiopathy	13.50	12.82	13	21561	4250	46660238
Acute lung injury	13.48	12.82	8	21566	1263	46663225
Neutrophilia	13.25	12.82	11	21563	2966	46661522
Drug tolerance decreased	12.99	12.82	11	21563	3048	46661440
Left ventricular dilatation	12.95	12.82	5	21569	302	46664186

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gout	697.11	11.70	326	25413	16989	29909750
Enthesopathy	155.98	11.70	67	25672	2839	29923900
Neuromyopathy	151.40	11.70	49	25690	923	29925816
Tenosynovitis	146.86	11.70	68	25671	3447	29923292
Drug interaction	141.81	11.70	434	25305	199134	29727605
Myopathy	130.11	11.70	92	25647	10494	29916245
Rhabdomyolysis	126.50	11.70	209	25530	63371	29863368
Acute kidney injury	124.42	11.70	514	25225	273328	29653411
Tongue disorder	116.31	11.70	62	25677	4260	29922479
Diarrhoea	113.80	11.70	576	25163	333527	29593212
Toxicity to various agents	104.64	11.70	362	25377	176821	29749918
C-reactive protein abnormal	103.99	11.70	63	25676	5530	29921209
Synovitis	88.97	11.70	71	25668	9712	29917027
Alanine aminotransferase abnormal	86.13	11.70	43	25696	2576	29924163
Familial mediterranean fever	79.56	11.70	15	25724	17	29926722
Pericarditis	68.90	11.70	58	25681	8548	29918191
Drug reaction with eosinophilia and systemic symptoms	66.74	11.70	101	25638	28387	29898352
Tendonitis	66.08	11.70	55	25684	7981	29918758
Drug abuse	58.14	11.70	3	25736	82069	29844670
Loss of personal independence in daily activities	52.79	11.70	78	25661	21457	29905282
Myopathy toxic	52.57	11.70	18	25721	406	29926333
Type 2 lepra reaction	50.22	11.70	17	25722	370	29926369
Blood uric acid increased	49.05	11.70	41	25698	5982	29920757
Aspartate aminotransferase increased	41.17	11.70	134	25605	63288	29863451
Behcet's syndrome	40.64	11.70	10	25729	64	29926675
Metabolic acidosis	40.08	11.70	95	25644	37366	29889373
Psoriatic arthropathy	39.94	11.70	58	25681	15703	29911036
Drug intolerance	37.22	11.70	104	25635	45187	29881552
Treatment failure	37.15	11.70	88	25651	34591	29892148
Therapeutic response decreased	35.50	11.70	70	25669	24279	29902460
Oligoasthenozoospermia	35.44	11.70	7	25732	12	29926727
Alanine aminotransferase increased	33.91	11.70	140	25599	74136	29852603
Gouty arthritis	33.74	11.70	17	25722	1038	29925701
Renal failure	31.47	11.70	204	25535	128762	29797977
Death	31.23	11.70	180	25559	357103	29569636
Spermatozoa progressive motility decreased	30.02	11.70	9	25730	130	29926609
Malignant neoplasm progression	27.30	11.70	14	25725	72273	29854466
Gouty tophus	25.81	11.70	8	25731	130	29926609
Myalgia	25.70	11.70	132	25607	76535	29850204
Herbal interaction	25.45	11.70	10	25729	336	29926403
Erythema	25.03	11.70	132	25607	77319	29849420
Hypertrophic osteoarthropathy	24.62	11.70	7	25732	83	29926656
Myositis	24.58	11.70	37	25702	10340	29916399
Agranulocytosis	22.76	11.70	55	25684	21887	29904852
Scrotal erythema	22.27	11.70	5	25734	20	29926719
Cholestasis	22.19	11.70	59	25680	24891	29901848
Pericardial effusion	21.93	11.70	53	25686	21091	29905648
Drug hypersensitivity	21.60	11.70	116	25623	68403	29858336
Insulin autoimmune syndrome	21.54	11.70	8	25731	230	29926509
Multiple organ dysfunction syndrome	21.06	11.70	109	25630	63378	29863361
Overdose	20.91	11.70	134	25605	84203	29842536
Bradycardia foetal	20.88	11.70	8	25731	251	29926488
Chondrocalcinosis	20.59	11.70	8	25731	261	29926478
Leukocytosis	20.30	11.70	52	25687	21450	29905289
Seizure	19.67	11.70	34	25705	98441	29828298
Disease progression	19.46	11.70	24	25715	79850	29846889
Serum amyloid A protein increased	18.71	11.70	4	25735	12	29926727
Mixed dementia	18.63	11.70	7	25732	208	29926531
Sinus arrhythmia	18.34	11.70	10	25729	718	29926021
Biopsy muscle abnormal	18.18	11.70	3	25736	0	29926739
Pneumonia	18.09	11.70	192	25547	334114	29592625
Hepatitis acute	17.85	11.70	26	25713	7057	29919682
Aggression	17.49	11.70	5	25734	36902	29889837
Genital ulceration	16.47	11.70	6	25733	163	29926576
Skin hyperpigmentation	15.82	11.70	16	25723	2978	29923761
Chondrocalcinosis pyrophosphate	15.26	11.70	9	25730	751	29925988
Thrombocytopenic purpura	14.72	11.70	10	25729	1068	29925671
Chronic kidney disease	14.71	11.70	68	25671	37770	29888969
Pancytopenia	14.69	11.70	124	25615	84928	29841811
Hepatosplenomegaly neonatal	14.68	11.70	4	25735	40	29926699
Somnolence	14.66	11.70	39	25700	96724	29830015
Thrombocytopenia	14.64	11.70	181	25558	136863	29789876
Angioedema	14.27	11.70	63	25676	34321	29892418
Blood creatine phosphokinase increased	13.65	11.70	74	25665	43774	29882965
Gastrointestinal disorder	13.59	11.70	54	25685	28083	29898656
Sperm concentration decreased	13.49	11.70	5	25734	143	29926596
Narcolepsy	13.46	11.70	7	25732	457	29926282
Cellulitis	13.27	11.70	77	25662	46707	29880032
Necrotising colitis	13.20	11.70	9	25730	967	29925772
Skin plaque	13.17	11.70	16	25723	3646	29923093
Stomatitis	12.95	11.70	8	25731	37271	29889468
Completed suicide	12.68	11.70	136	25603	99356	29827383
Quadriparesis	12.67	11.70	9	25730	1032	29925707
Thrombocytosis	12.42	11.70	15	25724	3398	29923341
Hepatocellular injury	12.39	11.70	49	25690	25422	29901317
Brain hypoxia	12.29	11.70	6	25733	342	29926397
Arthralgia	12.27	11.70	174	25565	135617	29791122

Pharmacologic Action:

Source	Code	Description
ATC	M04AC01	MUSCULO-SKELETAL SYSTEM ANTIGOUT PREPARATIONS ANTIGOUT PREPARATIONS Preparations with no effect on uric acid metabolism
FDA MoA	N0000000239	P-Glycoprotein Interactions
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D006074	Gout Suppressants
MeSH PA	D050257	Tubulin Modulators
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
CHEBI has role	CHEBI:25435	mutagens
CHEBI has role	CHEBI:35845	gout suppressants
CHEBI has role	CHEBI:67079	antiinflammatory agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Familial Mediterranean fever	indication	12579009	DOID:2987
Chronic gouty arthritis	indication	68451005
Gout	indication	90560007	DOID:13189
Gout Prevention	indication
Peptic ulcer	contraindication	13200003	DOID:750
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diarrhea	contraindication	62315008
Leukopenia	contraindication	84828003	DOID:615
Anemia due to enzyme deficiency	contraindication	111577008
Disorder of muscle	contraindication	129565002	DOID:423
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Impaired renal function disorder	contraindication	197663003
Rhabdomyolysis	contraindication	240131006
Renal dialysis	contraindication	265764009
Uric acid renal calculus	contraindication	274401005
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Aplastic anemia	contraindication	306058006	DOID:12449
Bone marrow depression	contraindication	307762000
Granulocytopenic disorder	contraindication	417672002
Vomiting	contraindication	422400008
Uric Acid Nephropathy Gout	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.19	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Multidrug resistance-associated protein 1	Transporter	P33527	MRP1_HUMAN				WOMBAT-PK
Glycine receptor subunit alpha-2	Ion channel	P23416	GLRA2_HUMAN		IC50	4.19	WOMBAT-PK
Tubulin beta-4B chain	Structural	P68371	TBB4B_HUMAN		Ki	5.24	WOMBAT-PK
Glycine receptor subunit alpha-1	Ion channel	P23415	GLRA1_HUMAN		IC50	3.49	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Kd	3.80	WOMBAT-PK
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Ki	4.19	WOMBAT-PK
Tubulin beta chain	Structural	P07437	TBB5_HUMAN	INHIBITOR	Ki	5.24	WOMBAT-PK
Tubulin	Structural		TBA1A_PIG TBB_PIG		Ki	5.24	CHEMBL
Tubulin alpha-1A chain	Structural		TBA1A_PIG		Ki	5.60	CHEMBL
Tubulin beta-2B chain	Structural		TBB2B_BOVIN		Ki	6.11	CHEMBL
Tubulin	Structural		Q862F3_BOVIN Q862L2_BOVIN TBB2B_BOVIN		IC50	6.10	CHEMBL
Tubulin polymerization-promoting protein	Unclassified		TPPP_BOVIN		EC50	6.12	CHEMBL

External reference:

ID	Source
4020930	VUID
N0000148412	NUI
D00570	KEGG_DRUG
4017416	VANDF
4020930	VANDF
C0009262	UMLSCUI
CHEBI:27882	CHEBI
LOC	PDB_CHEM_ID
CHEMBL107	ChEMBL_ID
DB01394	DRUGBANK_ID
D003078	MESH_DESCRIPTOR_UI
6167	PUBCHEM_CID
2367	IUPHAR_LIGAND_ID
SML2Y3J35T	UNII
2683	RXNORM
4493	MMSL
581	MMSL
d00150	MMSL
002372	NDDF
387413002	SNOMEDCT_US
73133000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0143-3018	CAPSULE	0.60 mg	ORAL	NDA	27 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0254-2008	TABLET, FILM COATED	0.60 mg	ORAL	NDA AUTHORIZED GENERIC	32 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1086	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	28 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2562	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	27 sections
Probenecid and Colchicine	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5325	TABLET	0.50 mg	ORAL	ANDA	13 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6732	CAPSULE	0.60 mg	ORAL	NDA	27 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7120	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	27 sections
Colcrys	HUMAN PRESCRIPTION DRUG LABEL	1	13310-119	TABLET, FILM COATED	0.60 mg	ORAL	NDA	29 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	42292-054	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	27 sections
Colcrys	HUMAN PRESCRIPTION DRUG LABEL	1	43353-854	TABLET, FILM COATED	0.60 mg	ORAL	NDA	28 sections
colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	43598-372	TABLET	0.60 mg	ORAL	ANDA	28 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3465	CAPSULE	0.60 mg	ORAL	NDA	27 sections
Probenecid and Colchicine	Human Prescription Drug Label	2	50742-263	TABLET	0.50 mg	ORAL	ANDA	13 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	51407-082	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	27 sections
Colcrys	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6256	TABLET, FILM COATED	0.60 mg	ORAL	NDA	29 sections
MITIGARE	HUMAN PRESCRIPTION DRUG LABEL	1	59467-318	CAPSULE	0.60 mg	ORAL	NDA	28 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	60687-358	CAPSULE	0.60 mg	ORAL	NDA	27 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	60687-389	TABLET, FILM COATED	0.60 mg	ORAL	NDA authorized generic	28 sections
Colcrys	HUMAN PRESCRIPTION DRUG LABEL	1	63187-292	TABLET, FILM COATED	0.60 mg	ORAL	NDA	29 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2166	TABLET, FILM COATED	0.60 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2167	TABLET, FILM COATED	0.60 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7422	CAPSULE	0.60 mg	ORAL	NDA	27 sections
colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8362	TABLET	0.60 mg	ORAL	ANDA	26 sections
Colcrys	HUMAN PRESCRIPTION DRUG LABEL	1	64764-119	TABLET, FILM COATED	0.60 mg	ORAL	NDA	30 sections
Probenecid and Colchicine	Human Prescription Drug Label	2	64980-149	TABLET	0.50 mg	ORAL	ANDA	13 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	65162-710	TABLET	0.60 mg	ORAL	ANDA	19 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	67296-1708	TABLET, FILM COATED	0.60 mg	ORAL	NDA authorized generic	28 sections
colchicine	Human Prescription Drug Label	1	67877-589	TABLET	0.60 mg	ORAL	ANDA	26 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	70010-002	TABLET, FILM COATED	0.60 mg	ORAL	ANDA	27 sections
Colchicine	HUMAN PRESCRIPTION DRUG LABEL	1	71205-310	TABLET, FILM COATED	0.60 mg	ORAL	NDA authorized generic	28 sections